Francesco Pierconti

2.2k citations
82 papers · 1.5k indexed · h-index 21

Francesco Pierconti

77 papers receiving 1.5k citations

Peers

Francesco Pierconti
Comparison fields: 5 of 98
  • Genetics 238
  • Pathology and Forensic Medicine 400
  • Oncology 591
  • Urology 110
  • Cancer Research 210
Replace Pramod Kumar Julka with:
Pramod Kumar Julka India
Antonio Cavaliere Italy
Tipu Nazeer United States
Zahid Kaleem United States
Annette Zimpfer Germany
Stefano Pizzolitto Italy
Giulio Fraternali Orcioni Italy
Mohammed Akhtar Saudi Arabia
Eble Jn United States
P Tosi Italy
Francesco Pierconti relative to Pramod Kumar Julka India Pramod Kumar Julka's profile →
Citations per field
00.5×
Pramod Kumar Julka · 1×
Citations per year

Countries citing papers authored by Francesco Pierconti

Since Specialization
Citations

This map shows the geographic impact of Francesco Pierconti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Pierconti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Pierconti more than expected).

Fields of papers citing papers by Francesco Pierconti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Pierconti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Pierconti. The network helps show where Francesco Pierconti may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Francesco Pierconti, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Francesco Pierconti Line = papers co-authored together Francesco Pierconti links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20251
2 20240
3 20231
4 20232
5 202310
6 202315
7 20232
8 20231
9 20232
10 20226
11 20224
12 20226
13 20229
14 20225
15 20220
16 202115
17 202057
18 20197
19 20198
20 201072

About Francesco Pierconti

Francesco Pierconti is a scholar working on Urology, Pulmonary and Respiratory Medicine and Oncology, having authored 82 papers that have together received 1.5k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (14 papers), Prostate Cancer Treatment and Research (13 papers), Urinary and Genital Oncology Studies (12 papers), Prostate Cancer Diagnosis and Treatment (11 papers), Urological Disorders and Treatments (9 papers), Renal cell carcinoma treatment (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Pelvic floor disorders treatments (6 papers). The work is most often cited by research in Genetics (238 citations), Pathology and Forensic Medicine (400 citations) and Oncology (591 citations). Francesco Pierconti has collaborated with scholars based in Italy, United States and Japan. Frequent co-authors include Luigi Maria Larocca, Maurizio Martini, Tonia Cenci, Roberto Pallini, Gianluca Gaïdano, Emilio Sacco, Lucia Ricci‐Vitiani, Vincenzo Fiorentino, Daniela Capello and Pier Francesco Bassi. Their work appears in journals such as Journal of Clinical Oncology, Blood and Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026